Kailera Therapeutics KLRA Insider Ownership

Updated Oct 10, 2026

In the last 12 months, insiders at Kailera Therapeutics made open-market purchases of $167.38 million (10.46Mn shares) and sold no shares on the open market.

• Behind Kailera Therapeutics' open-market purchases in the past 12 months were 3 insiders, and no insider sold.
• Among KLRA's insiders, Andrew T. Kaplan (Director and 10% owner) was the top open-market buyer in the past 12 months, with $134.38 million of stock purchased (8.4Mn shares) and the latest purchase on April 20, 2026.
• Apart from open-market trades, KLRA insiders acquired 60.7Mn shares through option exercises and conversions in the past 12 months.
• Per Business Quant, KLRA insiders together hold 61.69Mn shares based on their latest Form 4 filings, or 47.59% of the 129.62Mn shares outstanding; that total is unchanged from 61.69Mn shares at the end of Q2 2026.
• Direct holdings account for 2.07Mn shares (3.36%) of KLRA's insider total, and indirect holdings through trusts, partnerships and family members for 59.62Mn shares (96.64%).
• KLRA's insider total is spread across 5 insiders who have filed a Form 4 in the past two years.
• KLRA's three largest insider shareholders, per their latest Form 4 filings, are Bain Capital Investors LLC (10% owner, 26.26Mn shares), Adam Koppel (Director and 10% owner, 22.58Mn shares) and RTW Investments, LP (10% owner, 10.78Mn shares).
• Bain Capital Investors LLC alone accounts for 42.56% of the shares held by Kailera Therapeutics insiders.
• In the past year, 19 insiders of Kailera Therapeutics submitted 20 Form 4 filings reporting trades, awards or other transactions.
• This summary of Kailera Therapeutics insider activity covers Form 4 filings through September 9, 2026.